Harrow (NASDAQ:HROW) and Jaguar Animal Health (NASDAQ:JAGX) Head-To-Head Review

Harrow (NASDAQ:HROW) and Jaguar Animal Health (NASDAQ:JAGX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, valuation, risk, institutional ownership, analyst recommendations, earnings and profitability.

Earnings & Valuation

This table compares Harrow and Jaguar Animal Health”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Harrow	$275.59 million	4.15	-$5.14 million	($1.00)	-30.48
Jaguar Animal Health	$11.51 million	0.11	-$53.43 million	($3,731.33)	-0.00

Harrow has higher revenue and earnings than Jaguar Animal Health. Harrow is trading at a lower price-to-earnings ratio than Jaguar Animal Health, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Harrow and Jaguar Animal Health’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Harrow	-13.51%	-38.00%	-3.37%
Jaguar Animal Health	-187.88%	N/A	-131.45%

Analyst Ratings

This is a breakdown of recent ratings for Harrow and Jaguar Animal Health, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Harrow	1	2	7	0	2.60
Jaguar Animal Health	1	0	0	0	1.00

Harrow currently has a consensus price target of $66.17, suggesting a potential upside of 117.08%. Given Harrow’s stronger consensus rating and higher possible upside, analysts clearly believe Harrow is more favorable than Jaguar Animal Health.

Volatility & Risk

Harrow has a beta of 0.19, indicating that its share price is 81% less volatile than the S&P 500. Comparatively, Jaguar Animal Health has a beta of -0.11, indicating that its share price is 111% less volatile than the S&P 500.

Institutional and Insider Ownership

72.8% of Harrow shares are owned by institutional investors. Comparatively, 12.0% of Jaguar Animal Health shares are owned by institutional investors. 12.8% of Harrow shares are owned by company insiders. Comparatively, 0.2% of Jaguar Animal Health shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Harrow beats Jaguar Animal Health on 12 of the 14 factors compared between the two stocks.

About Harrow

Harrow, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.

About Jaguar Animal Health

Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company's products include Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing NP-300, a second-generation antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.